-
Mirikizumab demonstrated sustained efficacy at week 52 in patients with moderate-to-severe Crohn’s disease. In the maintenance period of the phase 2 SERENITY trial, few patients discontinued due to adverse events.
-
A Japanese study showed that the presence or absence of cholecystectomy does not affect biliary tract problems or mortality in patients ≥80 years old. Follow-up may be appropriate, without surgery.
-
The uroguanylin-analog plecanatide is an effective symptomatic treatment for patients with IBS-C. An early clinical response appeared to be predictive of overall response after 12 weeks.
-
TNF antagonists do not appear to be associated with severe COVID-19, a large, international registry to monitor outcomes of IBD patients with confirmed COVID-19 found.
-
High-quality therapeutic ERCP, EUS, luminal stenting, and dilatation, can be delivered safely to appropriately prioritized patients during the COVID-19 pandemic.
-
STARDUST is the first randomized treat-to-target trial using endoscopy at week 16 to guide dose escalation in Crohn’s disease patients. T2T could be an additional tool for ustekinumab dosing decisions.
-
Sports are key for this patient group. Hypoglycemia should be avoided by supplementing carbohydrate intake, preprandial and basal insulin doses reduction, and combining aerobic exercise with other activities.
-
Oncological treatment with PD1 or PD-L1 inhibitors can trigger type 1 diabetes. This undesirable effect usually occurs early, often accompanied by acute ketoacidosis. Current data on the issue were presented.
-
People who suffer from diabetes mellitus and have elevated uric acid levels, often also have diabetic nephropathy. The question was clearly answered: uric acid is a biomarker and not a risk factor.
-
Hypoglycemia in diabetes types 1 and 2 patients has not decreased in recent years despite numerous improvements. The role of C-peptide in hypoglycemia and modern techniques to prevent it were discussed.
-
Dapagliflozin reduced kidney failure risk in patients with CKD, the risk of cardiovascular death or hospitalization due to heart failure, and the SGLT2 inhibitor prolonged survival.
-
Björn Eliasson presented non-insulin-containing therapies, such as dapagliflozin, while Eelco de Koning discussed the pros and cons of pancreatic and beta-cell transplantation.
-
The previously-released trial results were presented with additional current data, supporting the inhibitor’s use as a further pillar for heart failure treatment in patients with reduced ejection fraction.
-
The EASD president speaks about the hot topics of this year's congress, new e-learning opportunities, and the measures taken by EASD to support its members in times of COVID-19
-
Flash glucose monitoring can expand the timeframe in which glucose level is in the range of 70-180 mg/dl, compared to blood glucose self-monitoring, and therefore shortening hypoglycemia phases.
-
Pulmonary fibrosis can occur secondarily after infection, especially in patients who suffered from severely impaired diffusion capacity during the acute infection.
-
Singing is as effective as classical pulmonary rehabilitation in COPD patients as a means of improving physical performance.
-
Physical activity should play a key role in multi-component interventions of sleep apnea patients as it has a positive influence on the Apnea-Hypopnea Index and risk factors for diseases such as diabetes.
-
An increasing variety of nicotine-containing products is available. The consumption of e-cigarettes, traditional cigarettes, and also cannabis, could be more harmful than smoking alone.
-
Results from a large pooled cohort study show that even less than 10 cigarettes a day significantly increases the risk of lung cancer or respiratory disease death.
